[{"id":"d4b3afea-d3d9-4419-8a44-fcb045a46c84","acronym":"LANDSCAPE 1011","url":"https://clinicaltrials.gov/study/NCT04585815","created_at":"2021-01-18T21:52:42.284Z","updated_at":"2024-07-02T16:35:11.290Z","phase":"Phase 1/2","brief_title":"Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study)","source_id_and_acronym":"NCT04585815 - LANDSCAPE 1011","lead_sponsor":"Pfizer","biomarkers":" PD-L1","pipe":" | ","alterations":" BRAF V600E • BRAF V600","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mektovi (binimetinib) • Braftovi (encorafenib) • axitinib • Zumrad (sasanlimab) • SEA-TGT"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 34","initiation":"Initiation: 11/10/2020","start_date":" 11/10/2020","primary_txt":" Primary completion: 05/17/2023","primary_completion_date":" 05/17/2023","study_txt":" Completion: 06/17/2024","study_completion_date":" 06/17/2024","last_update_posted":"2024-04-05"}]